Skip to main content

$0.042 -0.001 (-2.33%)

High

$0.04

Low

$0.04

Trades

17

Turnover

$24,861

Volume

582,113
30 June 2023 at 3:56pm
Register to track ACR and receive email alerts.
Subject
ACR Ann: Appendix 3Y Brooke

ACR Ann: Application for quotation of securities - ACR

ACR Ann: 4th FDA ANDA approval received - Dapsone Gel, 5%

ACR Ann: Appendix 3Y Dobinson

ACR Ann: Appendix 3Y Brumley

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Quarterly Activities/Appendix 4C Cash Flow Report

ACR Ann: Appendix 3Y Oldham

ACR Ann: Appendix 3Y Brooke

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Notification of cessation of securities - ACR

ACR Ann: Appendix 3Y Buumley

ACR Ann: Appendix 3Y Dobinson

ACR Ann: Appendix 3Y Brumley

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Appendix 4D and Half Year Report

ACR Ann: Notification regarding unquoted securities - ACR

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Quarterly Activities / Appendix 4C Cashflow Report

ACR Ann: Gedeon Richter buyout Lenzetto Royalties for EUR4.1million

ACR Ann: Positive FDA Remote Regulatory Assessment

ACR Ann: Launch of prilocaine and lidocaine cream in United States

ACR Ann: Mutual Termination of Co-Development Agreement

ACR Ann: Appendix 3Y - Brooke

ACR Ann: Appendix 3Y - Dobinson

ACR Ann: Appendix 3Y - Brumley

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Appendix 3Y Dobinson

ACR Ann: Appendix 3Y Brooke

ACR Ann: Appendix 3Y Oldham

ACR Ann: Appendix 3Y Brumley

ACR Ann: Notification regarding unquoted securities - ACR

ACR Ann: Results of AGM

ACR Ann: Chairman and CEO address to AGM

ACR Ann: Final FY22 R&D Tax Incentive balance received (OSF)

ACR Ann: Appendix 3Y Geoff Brooke

ACR Ann: Appendix 3Y Ross Dobinson

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Quarterly Activities/Appendix 4C Cash Flow Report

ACR Ann: R&D Tax Incentive receipt - Overseas Finding

ACR Ann: Notice of Annual General Meeting/Proxy Form

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Remaining balance of R&D Tax Incentive Rebate received

ACR Ann: R&D Tax Incentive Rebate received

ACR Ann: Notification of cessation of securities - ACR

ACR Ann: Appendix 3Y - Brumley

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Appendix 4G and Corporate Governance Statement

ACR Ann: Appendix 4E and FY22 Annual Report

ACR Ann: Acrux's sixth generic dossier accepted by FDA for review

Register to track ACR and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL